Phenotypic variation in anti-Mullerian hormone (AMH) production per follicle in women with polycystic ovary syndrome (PCOS) and isolated polycystic ovarian morphology (PCOM): an observational cross-sectional study

References

• Fallat ME, Siow Y, Marra M, et al. Müllerian-inhibiting substance in follicular fluid and serum: a comparison of patients with tubal factor infertility, polycystic ovary syndrome, and endometriosis. Fertil Steril 1997;67:962–5
   PubMed Web of Science ®Google Scholar
• Pigny P, Merlen E, Robert Y, et al. Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab 2003;88:5957–62
   PubMed Web of Science ®Google Scholar
• Laven JS, Mulders AG, Visser JA, et al. Anti-Müllerian hormone serum concentrations in normo-ovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab 2004;89:318–23
   PubMed Web of Science ®Google Scholar
• Pellatt L, Hanna L, Brincat M, et al. Granulosa cell production of anti-Müllerian hormone is increased in polycystic ovaries. J Clin Endocrinol Metab 2007;92:240–5
   PubMed Web of Science ®Google Scholar
• Homburg R, Ray A, Bhide P, et al. The relationship of serum anti-Müllerian hormone with polycystic ovarian morphology and polycystic ovary syndrome: a prospective cohort study. Hum Reprod 2013;28:1077–83
   PubMed Web of Science ®Google Scholar
• Cook CL, Siow Y, Brenner AG, Fallat ME. Relationship between serum Mullerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovarian syndrome and normal women. Fertil Steril 2002;77:141–6
   PubMed Web of Science ®Google Scholar
• Pigny P, Jonard S, Robert Y, Dewailly D. Serum anti-Mullerian hormone as a surrogate marker for antral follicle count for definition of the polycystic ovarian syndrome. J Clin Endocrinol Metab 2006;91:941–5
   PubMed Web of Science ®Google Scholar
• Catteau-Jonard S, Jamin SP, Leclerc A, et al. Anti-Mullerian hormone, its receptor, FSH receptor, and androgen receptor genes are overexpressed by granulosa cells from stimulated follicles in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2008;93:4456–61
   PubMed Web of Science ®Google Scholar
• Bhide P, Dilgil M, Gudi A, et al. Each small antral follicle in ovaries of women with polycystic ovary syndrome produces more anti-Mullerian hormone than its counterpart in a normal ovary: an observational cross-sectional study. Fertil Steril 2015;103:537–41
   PubMed Web of Science ®Google Scholar
• Nardo LG, Yates AP, Roberts SA, et al. The relationship between AMH, androgens, insulin resistance and basal ovarian status in non-obese subfertile women with and without polycystic ovarian syndrome. Hum Reprod 2009;24:2917–23
   PubMed Web of Science ®Google Scholar
• Grossman MP, Nakajima ST, Fallat ME, Siow Y. Müllerian-inhibiting substance inhibits cytochrome P450 aromatase activity in human granulosa lutein cell culture. Fertil Steril 2008;89:1364–70
   PubMed Web of Science ®Google Scholar
• Durlinger AL1, Gruijters MJ, Kramer P, et al. Anti-Müllerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology 2001;142:4891–9
   PubMed Web of Science ®Google Scholar
• Di Clemente N, Goxe B, Remmy J, et al. Inhibitory effect of MAH upon the expression of aromatase and LH receptors by cultured granulose cells of rat and porcine immature ovaries. Endocrine 1994;2:553–8
   Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19–25
   Web of Science ®Google Scholar
• Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update 2003;9:505–14
   PubMed Web of Science ®Google Scholar
• Treloar AE, Boynton RE, Behn BG, et al. Variation of the human menstrual cycle through reproductive life. Int J Fertil 1967;12:77–126
   PubMedGoogle Scholar
• Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 1981;140:815–30
   PubMed Web of Science ®Google Scholar
• Barth JH, Field HP, Yasmin E, Balen AH. Defining hyperandrogenism in polycystic ovary syndrome: measurement of testosterone and androstenedione by liquid chromatography-tandem mass spectrometry and analysis by receiver operator characteristic plots. Eur J Endocrinol 2010;162:611–5
   PubMed Web of Science ®Google Scholar
• Alebić MŠ, Stojanović N, Duhamel A, Dewailly D. The phenotypic diversity in per-follicle anti-Müllerian hormone production in polycystic ovary syndrome. Hum Reprod 2015;30:1927–33
   PubMed Web of Science ®Google Scholar
• Das M, Gillott DJ, Saridogan E, Djahanbakhch O. Anti-Mullerian hormone is increased in follicular fluid from unstimulated ovaries in women with polycystic ovary syndrome. Hum Reprod 2008;23:2122–6
   PubMed Web of Science ®Google Scholar
• Carlsen SM1, Vanky E, Fleming R. Anti-Müllerian hormone concentrations in androgen-suppressed women with polycystic ovary syndrome. Hum Reprod 2009;24:1732–8
   PubMed Web of Science ®Google Scholar
• Sahmay S, Atakul N, Oncul M, et al. Serum anti-Mullerian hormone levels in the main phenotypes of polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2013;170:157–61
   PubMed Web of Science ®Google Scholar
• Dewailly D, Alebić MSˇ, Duhamel A, Stojanović N, Using cluster analysis to identify a homogeneous subpopulation of women with polycystic ovarian morphology in a population of non-hyperandrogenic women with regular menstrual cycles. Hum Reprod 2014;29:2536–43
   PubMed Web of Science ®Google Scholar
• Vendola KA, Zhou J, Adesanya OO, et al. Androgens stimulate early stages of follicular growth in the primate ovary. J Clin Invest 1998;10:2622–9
   Web of Science ®Google Scholar
• Jonard S, Dewailly D. The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Hum Reprod Update 2004;10:107–17
   PubMed Web of Science ®Google Scholar
• Homburg R. Androgen circle of polycystic ovary syndrome. Hum Reprod 2009;24:1548–55
   PubMed Web of Science ®Google Scholar
• Dewailly D, Robin G, Peigne M, et al. Interactions between androgens, FSH, anti-Müllerian hormone and estradiol during folliculogenesis in the human normal and polycystic ovary. Hum Reprod Update 2016;22:709–24
   PubMed Web of Science ®Google Scholar
• Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666–72
   PubMed Web of Science ®Google Scholar
• Carmina E. Ovarian and adrenal hyperandrogenism. Ann N Y Acad Sci 2006;1092:130–7
   PubMed Web of Science ®Google Scholar
• Carmina E, Lobo RA. Prevalence and metabolic characteristics of adrenal androgen excess in hyperandrogenic women with different phenotypes. J Endocrinol Invest 2007;30:111–6
   PubMed Web of Science ®Google Scholar
• Stanczyk FZ, Chang L, Carmina E, et al. Is 11 beta-hydroxyandrostenedione a better marker of adrenal androgen excess than dehydroepiandrosterone sulfate? Am J Obstet Gynecol 1991;165:1837–42
   PubMed Web of Science ®Google Scholar
• Rosner W, Auchus RJ, Azziz R, et al. Position statement: utility, limitations, and pitfalls in measuring testosterone: an endocrine society position statement. J Clin Endocrinol Metab 2007;92:405–13
   PubMed Web of Science ®Google Scholar
• Janse F, Eijkemans MJ, Goverde AJ, et al. Assessment of androgen concentration in women: liquid chromatography–tandem mass spectrometry and extraction RIA show comparable results. Eur J Endocrinol 2011;165:925–33
   PubMed Web of Science ®Google Scholar
• Vesper HW, Bhasin S, Wang C, et al. Interlaboratory comparison study of serum total testosterone [corrected] measurements performed by mass spectrometry methods. Steroids 2009;74:498–503
   PubMed Web of Science ®Google Scholar
• Tal R, Seifer DB, Khanimov M, et al. Characterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes. Am J Obstet Gynecol 2014;211:59.e1–8
   Web of Science ®Google Scholar
• La Marca A, Orvieto R, Giulini S, et al. Mullerian-inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics. Fertil Steril 2004;82:970–2
   PubMed Web of Science ®Google Scholar
• Robinson S, Kiddy D, Gelding SV, et al. The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries. Clin Endocrinol (Oxf) 1993;39:351–5
   PubMed Web of Science ®Google Scholar
• Chang WY, Knochenhauer ES, Bartolucci AA, Azziz R. Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterisation of the four main groups. Fertil Steril 2005;83:1717–23
   PubMed Web of Science ®Google Scholar
• Conway GS, Honour JW, Jacobs H. Heterogeneity of the polycystic ovary syndrome: clinical, endocrine and ultrasound features in 556 patients. Clin Endocrinol (Oxf) 1989;30:459–70
   PubMed Web of Science ®Google Scholar
• Jayagopal V, Kilpatrick ES, Jennings PE, et al. The biological variation of testosterone and sex hormone-binding globulin (SHBG) in polycystic ovarian syndrome: implications for SHBG as a surrogate marker of insulin resistance. J Clin Endocrinol Metab 2003;88:1528–33
   PubMed Web of Science ®Google Scholar
• Chen MJ, Yang WS, Chen CL, et al. The relationship between anti-Mullerian hormone, androgen and insulin resistance on the number of antral follicles in women with the polycystic ovary syndrome. Hum Reprod 2008;23:952–7
   PubMed Web of Science ®Google Scholar
• Jeppesen JV, Anderson RA, Kelsey TW, et al. Which follicles make the most anti-Mullerian hormone in humans? Evidence for an abrupt decline in AMH production at the time of follicle selection. Mol Hum Reprod 2013;19:519–27
   PubMed Web of Science ®Google Scholar
• Executive Summary. National Institutes of Health. Evidence-based Methodology Workshop on Polycystic Ovary Syndrome. December 3–5, 2012. Available from: https://prevention.nih.gov/docs/programs/pcos/FinalReport.pdf
   Google Scholar